Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Rheumatoid Arthritis

Free Subscription Articles published in Ann Rheum Dis Retrieve available abstracts of 375 articles: HTML format

Single Articles

November 2024
1. LIDAR M, Rimar D, David P, Jacoby E, et al
   CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
   Ann Rheum Dis. 2024 Nov 27:ard-2024-226437. doi: 10.1136/ard-2024-226437.
   PubMed    
   
   
   
2. LIU J, Jiang Y, Zhang S, Liu S, et al
   Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
   Ann Rheum Dis. 2024 Nov 27:ard-2024-226385. doi: 10.1136/ard-2024-226385.
   PubMed     Abstract available
   
   
   
3. FAUTREL B, Mitrovic S, De Matteis A, Bindoli S, et al
   EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.
   Ann Rheum Dis. 2024;83:1614-1627.
   PubMed     Abstract available
   
   
   
4. BINDOLI S, De Matteis A, Mitrovic S, Fautrel B, et al
   Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
   Ann Rheum Dis. 2024;83:1731-1747.
   PubMed     Abstract available
   
   
   
5. DE MATTEIS A, Bindoli S, De Benedetti F, Carmona L, et al
   Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease.
   Ann Rheum Dis. 2024;83:1748-1761.
   PubMed     Abstract available
   
   
   
6. KACHLER K, Andreev D, Thapa S, Royzman D, et al
   Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis.
   Ann Rheum Dis. 2024;83:1691-1706.
   PubMed     Abstract available
   
   
   
7. BAKER KF, Spierings J, Brom M, Radstake T, et al
   Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
   Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772.
   PubMed    
   
   
   
8. VENKEN K, Jarlborg M, Stevenaert F, Malfait TLA, et al
   Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smoking.
   Ann Rheum Dis. 2024 Nov 8:ard-2024-226284. doi: 10.1136/ard-2024-226284.
   PubMed     Abstract available
   
   
   
9. ROONEY CM, Jeffery IB, Mankia K, Wilcox MH, et al
   Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study.
   Ann Rheum Dis. 2024 Nov 8:ard-2024-226362. doi: 10.1136/ard-2024-226362.
   PubMed     Abstract available
   
   
   
10. KRONZER VL, Williamson KA, Hayashi K, Atkinson EJ, et al
    Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk.
    Ann Rheum Dis. 2024 Nov 1:ard-2024-226391. doi: 10.1136/ard-2024-226391.
    PubMed     Abstract available
    
    
    
11. ZHENG L, Gu M, Li X, Hu X, et al
    ITGA5(+) synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Nov 1:ard-2024-225778. doi: 10.1136/ard-2024-225778.
    PubMed     Abstract available
    
    
    October 2024
12. RUYSSEN-WITRAND A, Brusq C, Masson M, Bongard V, et al
    Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo-controlled, double-blind trial.
    Ann Rheum Dis. 2024 Oct 29:ard-2024-226620. doi: 10.1136/ard-2024-226620.
    PubMed     Abstract available
    
    
    
13. 
    Correction: Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ann Rheum Dis. 2024;83:e27.
    PubMed    
    
    
    
14. FEIST E, Fleischmann RM, Fatenejad S, Bukhanova D, et al
    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
    Ann Rheum Dis. 2024;83:1454-1464.
    PubMed     Abstract available
    
    
    
15. KUBO S, Miyazaki Y, Nishino T, Fujita Y, et al
    Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
    Ann Rheum Dis. 2024 Oct 4:ard-2024-226228. doi: 10.1136/ard-2024-226228.
    PubMed     Abstract available
    
    
    
16. TAMAI H, Ikeda K, Miyamoto T, Taguchi H, et al
    Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
    Ann Rheum Dis. 2024 Oct 4:ard-2024-226350. doi: 10.1136/ard-2024-226350.
    PubMed     Abstract available
    
    
    September 2024
17. MAURO D, Lin X, Pontarini E, Wehr P, et al
    CD8(+) tissue-resident memory T cells are expanded in primary Sjogren's disease and can be therapeutically targeted by CD103 blockade.
    Ann Rheum Dis. 2024;83:1345-1357.
    PubMed     Abstract available
    
    
    
18. HOFFMANN MH, Kirchner H, Kronke G, Riemekasten G, et al
    Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases.
    Ann Rheum Dis. 2024;83:1233-1253.
    PubMed     Abstract available
    
    
    
19. VAN MULLIGEN E, Bour SS, Goossens LMA, de Jong PHP, et al
    Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial.
    Ann Rheum Dis. 2024 Sep 18:ard-2024-226286. doi: 10.1136/ard-2024-226286.
    PubMed     Abstract available
    
    
    
20. DEANE KD, Holers VM, Emery P, Mankia K, et al
    Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
    Ann Rheum Dis. 2024 Sep 6:ard-2023-224211. doi: 10.1136/ard-2023-224211.
    PubMed     Abstract available
    
    
    
21. QIU F, Xie D, Chen H, Wang Z, et al
    Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis.
    Ann Rheum Dis. 2024 Sep 4:ard-2024-225565. doi: 10.1136/ard-2024-225565.
    PubMed     Abstract available
    
    
    August 2024
22. PARKER M, Zheng Z, Lasarev MR, Larsen MC, et al
    Novel autoantibodies help diagnose anti-SSA antibody negative Sjogren disease and predict abnormal labial salivary gland pathology.
    Ann Rheum Dis. 2024;83:1169-1180.
    PubMed     Abstract available
    
    
    
23. KHIDIR SJH, Toes REM, van Mulligen E, van der Helm-van Mil AHM, et al
    Is tooth extraction as proxy for periodontal disease related to the development of RA? Lessons from a longitudinal study in the at-risk stage of clinically suspect arthralgia.
    Ann Rheum Dis. 2024;83:1227-1229.
    PubMed    
    
    
    
24. FUKUI S, Winkelmayer WC, Tedeschi SK, Marrugo J, et al
    Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.
    Ann Rheum Dis. 2024 Aug 21:ard-2024-226156. doi: 10.1136/ard-2024-226156.
    PubMed     Abstract available
    
    
    
25. TU J, Chen W, Huang W, Wang X, et al
    Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.
    Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. doi: 10.1136/ard-2024-226067.
    PubMed     Abstract available
    
    
    
26. WU H, Yuan H, Zhang J, He T, et al
    Helicobacter pylori upregulates PAD4 expression via stabilising HIF-1alpha to exacerbate rheumatoid arthritis.
    Ann Rheum Dis. 2024 Aug 6:ard-2023-225306. doi: 10.1136/ard-2023-225306.
    PubMed     Abstract available
    
    
    July 2024
27. HU F, Li X, Liu K, Li Y, et al
    Rheumatoid arthritis patients harbour aberrant enteric bacteriophages with autoimmunity-provoking potential: a paired sibling study.
    Ann Rheum Dis. 2024 Jul 31:ard-2024-225564. doi: 10.1136/ard-2024-225564.
    PubMed     Abstract available
    
    
    
28. LEND K, Lampa J, Padyukov L, Hetland ML, et al
    Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.
    Ann Rheum Dis. 2024 Jul 30:ard-2024-226024. doi: 10.1136/ard-2024-226024.
    PubMed     Abstract available
    
    
    
29. VAN MULLIGEN E, Rutten-van Molken M, van der Helm-van Mil A
    Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?
    Ann Rheum Dis. 2024 Jul 17:ard-2024-225746. doi: 10.1136/ard-2024-225746.
    PubMed     Abstract available
    
    
    
30. GENTE K, Feisst M, Marx D, Klika KD, et al
    Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
    Ann Rheum Dis. 2024;83:974-983.
    PubMed     Abstract available
    
    
    
31. GUPTA S, Yamada E, Nakamura H, Perez P, et al
    Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjogren's disease.
    Ann Rheum Dis. 2024;83:1034-1047.
    PubMed     Abstract available
    
    
    
32. YOSHIMURA Y, Yamanouchi M, Mizuno H, Ikuma D, et al
    Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
    Ann Rheum Dis. 2024 Jul 4:ard-2024-225914. doi: 10.1136/ard-2024-225914.
    PubMed     Abstract available
    
    
    June 2024
33. HAGHIKIA A, Hegelmaier T, Wolleschak D, Bottcher M, et al
    Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis.
    Ann Rheum Dis. 2024 Jun 27:ard-2024-226017. doi: 10.1136/ard-2024-226017.
    PubMed    
    
    
    May 2024
34. BAERWALD C, Stemmler E, Gnuchtel S, Jeromin K, et al
    Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain.
    Ann Rheum Dis. 2024 May 30:ard-2023-225414. doi: 10.1136/ard-2023-225414.
    PubMed     Abstract available
    
    
    
35. PISANIELLO HL, Lester SE, Russell O, Black R, et al
    The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).
    Ann Rheum Dis. 2024 May 29:ard-2024-225696. doi: 10.1136/ard-2024-225696.
    PubMed    
    
    
    
36. BURMESTER GR, Gottenberg JE, Caporali R, Winthrop KL, et al
    Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
    Ann Rheum Dis. 2024 May 23:ard-2024-225759. doi: 10.1136/ard-2024-225759.
    PubMed     Abstract available
    
    
    
37. LAGE-HANSEN PR, Svendsen N, Kirkham J, Nielsen SM, et al
    Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set.
    Ann Rheum Dis. 2024 May 22:ard-2024-225523. doi: 10.1136/ard-2024-225523.
    PubMed     Abstract available
    
    
    
38. BECKMANN D, Krause A, Hansen U, Kiener HP, et al
    Focal adhesion protein Lasp1 links the Arp2/3 complex to adherens junctions and promotes motility of arthritic fibroblast-like synoviocytes.
    Ann Rheum Dis. 2024;83:816-819.
    PubMed    
    
    
    
39. LIU D, Kuang Y, Chen S, Li R, et al
    NAT10 promotes synovial aggression by increasing the stability and translation of N4-acetylated PTX3 mRNA in rheumatoid arthritis.
    Ann Rheum Dis. 2024 May 8:ard-2023-225343. doi: 10.1136/ard-2023-225343.
    PubMed     Abstract available
    
    
    April 2024
40. IKDAHL E, Semb AG, Kerola AM
    No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register.
    Ann Rheum Dis. 2024 Apr 23:ard-2024-225758. doi: 10.1136/ard-2024-225758.
    PubMed    
    
    
    
41. LUO X, Ren Y, Chen Y
    Gender imbalance in expert panels of recommendations in rheumatology.
    Ann Rheum Dis. 2024;83:682-684.
    PubMed    
    
    
    
42. HERNANDEZ-CRUZ B, Otero-Varela L, Freire-Gonzalez M, Busquets-Perez N, et al
    Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Ann Rheum Dis. 2024 Apr 9:ard-2023-225271. doi: 10.1136/ard-2023-225271.
    PubMed     Abstract available
    
    
    March 2024
43. COHEN P, Ziff D, Lipsky PE
    Morris Ziff.
    Ann Rheum Dis. 2024;83:417-420.
    PubMed    
    
    
    
44. WINTHROP KL, Mease P, Kerschbaumer A, Voll RE, et al
    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
    Ann Rheum Dis. 2024;83:409-416.
    PubMed     Abstract available
    
    
    
45. MELOKHINA V, Paulshus Sundlisaeter N, Sexton J, Sundin U, et al
    Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
    Ann Rheum Dis. 2024;83:540-541.
    PubMed    
    
    
    February 2024
46. HE Y, Aoun M, Xu Z, Holmdahl R, et al
    Shift in perspective: autoimmunity protecting against rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 27:ard-2023-225237. doi: 10.1136/ard-2023-225237.
    PubMed     Abstract available
    
    
    
47. VAN DER WOUDE D, Toes REM
    Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?
    Ann Rheum Dis. 2024 Feb 20:ard-2023-224103. doi: 10.1136/ard-2023-224103.
    PubMed     Abstract available
    
    
    
48. 
    Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study.
    Ann Rheum Dis. 2024;83:e8.
    PubMed    
    
    
    
49. 
    Correction: A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis.
    Ann Rheum Dis. 2024;83:e9.
    PubMed    
    
    
    
50. TANG Z, Shi H, Liu HL, Cheng X, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e4.
    PubMed    
    
    
    
51. BARBHAIYA M, Zuily S, Hendry AM, Manneville F, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al.
    Ann Rheum Dis. 2024;83:e5.
    PubMed    
    
    
    
52. DAMOISEAUX J, van Beers J
    Correspondence on "ACR/EULAR antiphospholipid syndrome classification criteria".
    Ann Rheum Dis. 2024;83:e6.
    PubMed    
    
    
    
53. ERKAN D, Barbhaiya M, Zuily S, Bertolaccini ML, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al.
    Ann Rheum Dis. 2024;83:e3.
    PubMed    
    
    
    
54. BARBHAIYA M, Zuily S, Bertolaccini ML, Willis R, et al
    Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.
    Ann Rheum Dis. 2024;83:e7.
    PubMed    
    
    
    
55. MIRO-MUR FA, Alijotas-Reig J, Anunciacion-Llunell A, Marques-Soares J, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e2.
    PubMed    
    
    
    
56. PEZOT M, Nocturne G, Belkhir R, Henry J, et al
    Obinutuzumab in patients with Sjogren's disease immunised against rituximab.
    Ann Rheum Dis. 2024;83:407-408.
    PubMed    
    
    
    
57. DORNER T, Kaul M, Szanto A, Tseng JC, et al
    Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Ann Rheum Dis. 2024;83:360-371.
    PubMed     Abstract available
    
    
    
58. CROWSON CS, Atkinson EJ, Kronzer VL, Kimbrough BA, et al
    Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis.
    Ann Rheum Dis. 2024 Feb 8:ard-2023-225093. doi: 10.1136/ard-2023-225093.
    PubMed     Abstract available
    
    
    
59. SCHENNING LCM, Ottevanger R, Quint KD, Tas SW, et al
    An ulcerating skin tumour in a patient with rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 5:ard-2023-225436. doi: 10.1136/ard-2023-225436.
    PubMed    
    
    
    
60. HU F, Shi L, Liu X, Chen Y, et al
    Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-alpha in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 1:ard-2023-224878. doi: 10.1136/ard-2023-224878.
    PubMed     Abstract available
    
    
    January 2024
61. WU G, Cao B, Zhai H, Liu B, et al
    EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.
    Ann Rheum Dis. 2024 Jan 25:ard-2023-224852. doi: 10.1136/ard-2023-224852.
    PubMed     Abstract available
    
    
    
62. HECKERT SL, Maassen JM, le Cessie S, Goekoop-Ruiterman YPM, et al
    Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
    Ann Rheum Dis. 2024;83:161-168.
    PubMed     Abstract available
    
    
    
63. BONELLI M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al
    Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Ann Rheum Dis. 2024;83:139-160.
    PubMed     Abstract available
    
    
    
64. TANAKA H, Okada Y, Nakayamada S, Miyazaki Y, et al
    Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
    Ann Rheum Dis. 2024;83:242-252.
    PubMed     Abstract available
    
    
    
65. DREHER M, Witte T, Hoeper K, Assmann G, et al
    Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.
    Ann Rheum Dis. 2024;83:184-193.
    PubMed     Abstract available
    
    
    
66. SCHIFF AE, Wang X, Patel NJ, Kawano Y, et al
    Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
    Ann Rheum Dis. 2024 Jan 10:ard-2023-225162. doi: 10.1136/ard-2023-225162.
    PubMed    
    
    
    
67. AVOUAC J, Hecquet S, Thomas M, Combier A, et al
    Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts.
    Ann Rheum Dis. 2024 Jan 5:ard-2023-225272. doi: 10.1136/ard-2023-225272.
    PubMed    
    
    
    
68. TEUWEN MMH, van Weely SFE, Vliet Vlieland TPM, van Wissen MAT, et al
    Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-224912. doi: 10.1136/ard-2023-224912.
    PubMed     Abstract available
    
    
    
69. BAKER JF, ODell JR, England BR, Giles JT, et al
    Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-225014. doi: 10.1136/ard-2023-225014.
    PubMed     Abstract available
    
    
    
70. 
    Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2024;83:e1.
    PubMed    
    
    
    
71. CAO S, Li Y, Song R, Meng X, et al
    L-arginine metabolism inhibits arthritis and inflammatory bone loss.
    Ann Rheum Dis. 2024;83:72-87.
    PubMed     Abstract available
    
    
    
72. BIJLSMA JWJ
    Annals of the Rheumatic Diseases collection on glucocorticoids (2020-2023): novel insights and advances in therapy.
    Ann Rheum Dis. 2024;83:4-8.
    PubMed    
    
    
    
73. BERRY JS, Tarn J, Casement J, Duret PM, et al
    Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
    Ann Rheum Dis. 2024;83:88-95.
    PubMed     Abstract available
    
    
    December 2023
74. AYMON R, Mongin D, Bergstra SA, Choquette D, et al
    Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Ann Rheum Dis. 2023 Dec 8:ard-2023-224670. doi: 10.1136/ard-2023-224670.
    PubMed     Abstract available
    
    
    
75. TRIAILLE C, Tilman G, Sokolova T, Loriot A, et al
    Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis.
    Ann Rheum Dis. 2023;82:1538-1546.
    PubMed     Abstract available
    
    
    
76. YAMADA H, Haraguchi A, Tsuru T, Kondo M, et al
    Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies.
    Ann Rheum Dis. 2023;82:1637-1638.
    PubMed    
    
    
    November 2023
77. LIEN HJT, Pedersen TT, Jakobsen B, Flatberg A, et al
    Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.
    Ann Rheum Dis. 2023 Nov 30:ard-2023-224644. doi: 10.1136/ard-2023-224644.
    PubMed     Abstract available
    
    
    
78. PERTSINIDOU E, Saevarsdottir S, Manivel VA, Klareskog L, et al
    In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
    Ann Rheum Dis. 2023 Nov 27:ard-2023-224728. doi: 10.1136/ard-2023-224728.
    PubMed     Abstract available
    
    
    
79. MOULIN D, Millard M, Taieb M, Michaudel C, et al
    Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
    Ann Rheum Dis. 2023 Nov 24:ard-2023-224014. doi: 10.1136/ard-2023-224014.
    PubMed     Abstract available
    
    
    
80. GOLDMANN K, Spiliopoulou A, Iakovliev A, Plant D, et al
    Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome.
    Ann Rheum Dis. 2023 Nov 18:ard-2023-224540. doi: 10.1136/ard-2023-224540.
    PubMed     Abstract available
    
    
    
81. SIMON TA, Dong L, Suissa S, Michaud K, et al
    Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
    Ann Rheum Dis. 2023 Nov 6:ard-2023-224356. doi: 10.1136/ard-2023-224356.
    PubMed     Abstract available
    
    
    
82. 
    Correction: Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e227.
    PubMed    
    
    
    
83. 
    Correction: Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2023;82:e222.
    PubMed    
    
    
    
84. WOLLHEIM FA
    Nanna Svartz (1890-1986) and the discovery of sulfasalazine.
    Ann Rheum Dis. 2023;82:1382-1386.
    PubMed    
    
    
    
85. SAVIANO A, Manosour AA, Raucci F, Merlino F, et al
    New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
    Ann Rheum Dis. 2023;82:1415-1428.
    PubMed     Abstract available
    
    
    
86. SCHERLINGER M, Schaeverbeke T
    Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'.
    Ann Rheum Dis. 2023;82:e221.
    PubMed    
    
    
    October 2023
87. WESTHOVENS R, Verschueren P
    Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023.
    Ann Rheum Dis. 2023 Oct 30:ard-2023-224904. doi: 10.1136/ard-2023-224904.
    PubMed    
    
    
    
88. KONZETT V, Kerschbaumer A, Smolen JS, Kristianslund EK, et al
    Definition of rheumatoid arthritis flare based on SDAI and CDAI.
    Ann Rheum Dis. 2023 Oct 27:ard-2023-224742. doi: 10.1136/ard-2023-224742.
    PubMed     Abstract available
    
    
    
89. VAN WESEMAEL TJ, Reijm S, Kawakami A, Dorjee AL, et al
    IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Oct 3:ard-2023-224553. doi: 10.1136/ard-2023-224553.
    PubMed    
    
    
    
90. 
    Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2023;82:e219.
    PubMed    
    
    
    
91. VAN MULLIGEN E, van der Helm-van Mil A, de Jong PHP
    Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
    Ann Rheum Dis. 2023;82:e217.
    PubMed    
    
    
    
92. MA KS, Chiang CH, Chen YW, Wang LT, et al
    Correspondence to 'Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production'.
    Ann Rheum Dis. 2023;82:e216.
    PubMed    
    
    
    September 2023
93. KONZETT V, Kerschbaumer A, Smolen JS, Aletaha D, et al
    Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 27:ard-2023-224477. doi: 10.1136/ard-2023-224477.
    PubMed     Abstract available
    
    
    
94. FLEISCHMANN RM, van der Heijde D, Strand V, Atsumi T, et al
    Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
    Ann Rheum Dis. 2023 Sep 12:ard-2023-224482. doi: 10.1136/ard-2023-224482.
    PubMed     Abstract available
    
    
    
95. YAP CF, Nair N, de Vries A, Loeff FC, et al
    HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 12:ard-2023-223955. doi: 10.1136/ard-2023-223955.
    PubMed    
    
    
    
96. TAYLOR PC, Weinblatt ME, McInnes IB, Atsumi T, et al
    Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
    Ann Rheum Dis. 2023 Sep 11:ard-2023-224449. doi: 10.1136/ard-2023-224449.
    PubMed     Abstract available
    
    
    
97. 
    News from EULAR.
    Ann Rheum Dis. 2023;82:1242.
    PubMed    
    
    
    
98. LONGOBARDI S, Lopez-Davis C, Khatri B, Georgescu C, et al
    Autoantibodies identify primary Sjogren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B.
    Ann Rheum Dis. 2023;82:1181-1190.
    PubMed     Abstract available
    
    
    
99. FERRI C, Giuggioli D, Raimondo V, Fallahi P, et al
    COVID-19 in Italian patients with rheumatic autoimmune systemic diseases.
    Ann Rheum Dis. 2023;82:e211.
    PubMed    
    
    
    August 2023
100. VAN OUWERKERK L, Verschueren P, Boers M, Emery P, et al
     Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
     Ann Rheum Dis. 2023 Aug 22:ard-2023-224270. doi: 10.1136/ard-2023-224270.
     PubMed     Abstract available
     
     
     
101. LILLEGRAVEN S, Paulshus Sundlisaeter N, Aga AB, Sexton J, et al
     Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
     Ann Rheum Dis. 2023 Aug 22:ard-2023-224476. doi: 10.1136/ard-2023-224476.
     PubMed     Abstract available
     
     
     
102. ALMAYALI AAH, Boers M, Hartman L, Opris D, et al
     Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
     Ann Rheum Dis. 2023 Aug 4:ard-2023-223977. doi: 10.1136/ard-2023-223977.
     PubMed     Abstract available
     
     
     
103. RUSSELL MD, Stovin C, Alveyn E, Adeyemi O, et al
     JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
     Ann Rheum Dis. 2023;82:1059-1067.
     PubMed     Abstract available
     
     
     
104. BERGSTRA SA, Sepriano A, Chopra A, Winchow LL, et al
     Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry.
     Ann Rheum Dis. 2023;82:1018-1024.
     PubMed     Abstract available
     
     
     
105. HUANG YT, Jenkins DA, Peek N, Dixon WG, et al
     High frequency of long-term opioid use among patients with rheumatic and musculoskeletal diseases initiating opioids for the first time.
     Ann Rheum Dis. 2023;82:1116-1117.
     PubMed    
     
     
     
106. LEE S, Choi E, Chae S, Koh JH, et al
     Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling.
     Ann Rheum Dis. 2023;82:1035-1048.
     PubMed     Abstract available
     
     
     
107. REINISCH W, Hellstrom W, Dolhain RJEM, Sikka S, et al
     Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
     Ann Rheum Dis. 2023;82:1049-1058.
     PubMed     Abstract available
     
     
     
108. DALBETH N, Neogi T
     Where are the women 'Heroes and Pillars of Rheumatology'?
     Ann Rheum Dis. 2023;82:e199.
     PubMed    
     
     
     July 2023
109. SO H, Lam TO, Meng H, Lam SHM, et al
     Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.
     Ann Rheum Dis. 2023 Jul 24:ard-2023-224185. doi: 10.1136/ard-2023-224185.
     PubMed     Abstract available
     
     
     
110. QIU YY, Neogi T, Muhammad LN, Song J, et al
     Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis.
     Ann Rheum Dis. 2023 Jul 19:ard-2023-224492. doi: 10.1136/ard-2023-224492.
     PubMed    
     
     
     
111. OZEN G, Pedro S, Michaud K
     Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2023 Jul 17:ard-2023-224339. doi: 10.1136/ard-2023-224339.
     PubMed     Abstract available
     
     
     
112. VAN ESVELD L, Cox JM, Kuijper TM, Bosch TM, et al
     Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
     Ann Rheum Dis. 2023 Jul 9:ard-2023-224190. doi: 10.1136/ard-2023-224190.
     PubMed     Abstract available
     
     
     
113. OSTERGAARD M, van Vollenhoven RF, Rudin A, Hetland ML, et al
     Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
     Ann Rheum Dis. 2023 Jul 9:ard-2023-224116. doi: 10.1136/ard-2023-224116.
     PubMed     Abstract available
     
     
     
114. KIMURA A, Takagi T, Thamamongood T, Sakamoto S, et al
     Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4.
     Ann Rheum Dis. 2023 Jul 2:ard-2023-224055. doi: 10.1136/ard-2023-224055.
     PubMed     Abstract available
     
     
     
115. OSKAM N, Ooijevaar-De Heer P, Kos D, Jeremiasse J, et al
     Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity.
     Ann Rheum Dis. 2023;82:945-956.
     PubMed     Abstract available
     
     
     
116. BASS AR, Abdel-Wahab N, Reid PD, Sparks JA, et al
     Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
     Ann Rheum Dis. 2023;82:920-926.
     PubMed     Abstract available
     
     
     
117. KRISTENSEN LE, Danese S, Yndestad A, Wang C, et al
     Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
     Ann Rheum Dis. 2023;82:901-910.
     PubMed     Abstract available
     
     
     
118. YAZICI H, Yazici Y
     Correspondence on 'classification criteria: time for a rethink 'by D Porter et al'.
     Ann Rheum Dis. 2023;82:e176.
     PubMed    
     
     
     
119. CACCIAPAGLIA F, Manfredi A, Erre G, Piga M, et al
     Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al. The impact of cardiovascular c
     Ann Rheum Dis. 2023;82:e159.
     PubMed    
     
     
     June 2023
120. KUGLER M, Dellinger M, Kartnig F, Muller L, et al
     Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
     Ann Rheum Dis. 2023 Jun 21:ard-2022-223396. doi: 10.1136/ard-2022-223396.
     PubMed     Abstract available
     
     
     
121. FLEISCHMANN R, Curtis JR, Charles-Schoeman C, Mysler E, et al
     Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
     Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916.
     PubMed     Abstract available
     
     
     
122. 
     News from EULAR.
     Ann Rheum Dis. 2023;82:886.
     PubMed    
     
     
     
123. DE BENEDETTI F, Grom AA, Brogan PA, Bracaglia C, et al
     Efficacy and safety of emapalumab in macrophage activation syndrome.
     Ann Rheum Dis. 2023;82:857-865.
     PubMed     Abstract available
     
     
     
124. STYRKARSDOTTIR U, Stefansdottir L, Thorleifsson G, Stefansson OA, et al
     Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect.
     Ann Rheum Dis. 2023;82:873-880.
     PubMed     Abstract available
     
     
     
125. LI T, Ge C, Kramer A, Sareila O, et al
     Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage.
     Ann Rheum Dis. 2023;82:799-808.
     PubMed     Abstract available
     
     
     
126. OSPELT C
     Site of invasion revisited: epigenetic drivers of joint destruction in RA.
     Ann Rheum Dis. 2023;82:734-739.
     PubMed     Abstract available
     
     
     
127. ALETAHA D, Kerschbaumer A, Kastrati K, Dejaco C, et al
     Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
     Ann Rheum Dis. 2023;82:773-787.
     PubMed     Abstract available
     
     
     
128. FELTEN R, Gottenberg JE
     Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff et al.
     Ann Rheum Dis. 2023;82:e149.
     PubMed    
     
     
     
129. DE WOLFF L, Arends S, Verstappen GM, Vissink A, et al
     Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised controlled trial'.
     Ann Rheum Dis. 2023;82:e148.
     PubMed    
     
     
     May 2023
130. TAKEUCHI T, Tanaka S, Murata M, Tanaka Y, et al
     Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial.
     Ann Rheum Dis. 2023 May 22:ard-2022-223759. doi: 10.1136/ard-2022-223759.
     PubMed     Abstract available
     
     
     
131. WINTHROP KL, Isaacs JD, Mease PJ, Boumpas DT, et al
     Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
     Ann Rheum Dis. 2023;82:594-598.
     PubMed     Abstract available
     
     
     
132. BAKER JF, England BR, Mikuls TR
     Response to: 'Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'' by Ruscitti et al.
     Ann Rheum Dis. 2023;82:e120.
     PubMed    
     
     
     
133. RUSCITTI P, Sesti G, Cipriani P, Gerli R, et al
     Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e119.
     PubMed    
     
     
     April 2023
134. BOERS M
     Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al.
     Ann Rheum Dis. 2023 Apr 20:ard-2022-223599. doi: 10.1136/ard-2022-223599.
     PubMed    
     
     
     
135. STUDENIC P, Aletaha D, Stamm TA, de Wit M, et al
     Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al.
     Ann Rheum Dis. 2023 Apr 20:ard-2022-223627. doi: 10.1136/ard-2022-223627.
     PubMed    
     
     
     
136. MEYER A, Sienes RE, Nijim W, Zanotti B, et al
     Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
     Ann Rheum Dis. 2023;82:483-495.
     PubMed     Abstract available
     
     
     
137. REUTER K, Rocca E
     Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e91.
     PubMed    
     
     
     
138. ZHENG BK
     Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
     Ann Rheum Dis. 2023;82:e93.
     PubMed    
     
     
     
139. GEORGIADIS AN, Pelechas E, Voulgari PV, Drosos AA, et al
     Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e89.
     PubMed    
     
     
     
140. PLEIN S, Buch MH
     Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis et al.
     Ann Rheum Dis. 2023;82:e90.
     PubMed    
     
     
     
141. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
     Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng.
     Ann Rheum Dis. 2023;82:e94.
     PubMed    
     
     
     
142. ZERVOU MI, Goulielmos GN
     Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'.
     Ann Rheum Dis. 2023;82:e87.
     PubMed    
     
     
     
143. CONRAD N, McInnes IB, Mcmurray JJV, Sattar N, et al
     Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
     Ann Rheum Dis. 2023;82:457-459.
     PubMed    
     
     
     
144. SHARMA C, Whittle S, Haghighi PD, Burstein F, et al
     Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'' by Reuter et al.
     Ann Rheum Dis. 2023;82:e92.
     PubMed    
     
     
     
145. MOLANDER V, Askling J
     Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et al.
     Ann Rheum Dis. 2023;82:e88.
     PubMed    
     
     
     March 2023
146. YAMADA S, Nagafuchi Y, Wang M, Ota M, et al
     Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance.
     Ann Rheum Dis. 2023 Mar 14:ard-2022-223645. doi: 10.1136/ard-2022-223645.
     PubMed     Abstract available
     
     
     
147. HUSS V, Bower H, Hellgren K, Frisell T, et al
     Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
     Ann Rheum Dis. 2023 Mar 3:ard-2022-223636. doi: 10.1136/ard-2022-223636.
     PubMed     Abstract available
     
     
     
148. 
     Correction: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
     Ann Rheum Dis. 2023;82:e76.
     PubMed    
     
     
     
149. 
     News from EULAR.
     Ann Rheum Dis. 2023;82:448.
     PubMed    
     
     
     
150. LOPES AP, Hillen MR, Hinrichs AC, Blokland SL, et al
     Deciphering the role of cDC2s in Sjogren's syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity.
     Ann Rheum Dis. 2023;82:374-383.
     PubMed     Abstract available
     
     
     
151. WANG B, Chen S, Xuan J, Li Y, et al
     Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'.
     Ann Rheum Dis. 2023;82:e67.
     PubMed    
     
     
     
152. FELTEN R, Gottenberg JE
     Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang et al.
     Ann Rheum Dis. 2023;82:e68.
     PubMed    
     
     
     
153. AYDIN SZ, Hepworth E, Tugwell P
     Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
     Ann Rheum Dis. 2023;82:e69.
     PubMed    
     
     
     
154. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
     Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al.
     Ann Rheum Dis. 2023;82:e70.
     PubMed    
     
     
     
155. MOUTSOPOULOS HM
     Correspondence on 'Jan Gosta Waldenstrom and rheumatology'.
     Ann Rheum Dis. 2023;82:e59.
     PubMed    
     
     
     
156. NOVELLA-NAVARRO M, Plasencia-Rodriguez C, Tornero C, Navarro-Compan V, et al
     Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e55.
     PubMed    
     
     
     
157. ROODENRIJS NMT, Welsing PMJ, van der Goes MC, Jacobs JW, et al
     Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al.
     Ann Rheum Dis. 2023;82:e56.
     PubMed    
     
     
     February 2023
158. SMITH SL, Alexander S, Nair N, Viatte S, et al
     Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
     Ann Rheum Dis. 2023 Feb 21:annrheumdis-2022-222519. doi: 10.1136/ard-2022-222519
     PubMed     Abstract available
     
     
     
159. FRISELL T, Bower H, Morin M, Baecklund E, et al
     Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
     Ann Rheum Dis. 2023 Feb 14:ard-2022-223762. doi: 10.1136/ard-2022-223762.
     PubMed     Abstract available
     
     
     
160. O'NEIL LJ, Oliveira CB, Wang X, Navarrete M, et al
     Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis.
     Ann Rheum Dis. 2023 Feb 3:ard-2022-223568. doi: 10.1136/ard-2022-223568.
     PubMed     Abstract available
     
     
     
161. 
     Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
     Ann Rheum Dis. 2023;82:e53.
     PubMed    
     
     
     
162. TARANNUM S, Widdifield J, Wu CF, Johnson SR, et al
     Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study.
     Ann Rheum Dis. 2023;82:283-291.
     PubMed     Abstract available
     
     
     
163. POMBO-SUAREZ M, Sanchez-Piedra C, Gomez-Reino J, Lauper K, et al
     After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
     Ann Rheum Dis. 2023;82:175-181.
     PubMed     Abstract available
     
     
     
164. HOSONO Y, Sie B, Pinal-Fernandez I, Pak K, et al
     Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies.
     Ann Rheum Dis. 2023;82:246-252.
     PubMed     Abstract available
     
     
     
165. SUN T, Ni J
     Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e50.
     PubMed    
     
     
     
166. GILBERT BTP, Finckh A, Alpizar Rodriguez D
     Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'' by Sun and Ni.
     Ann Rheum Dis. 2023;82:e51.
     PubMed    
     
     
     
167. DE COCK D, Soenen I, Bertrand D, Pazmino S, et al
     Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'.
     Ann Rheum Dis. 2023;82:e44.
     PubMed    
     
     
     
168. RUYSSEN-WITRAND A, Soubrier M, Basch A, Truchetet ME, et al
     Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'.
     Ann Rheum Dis. 2023;82:e32.
     PubMed    
     
     
     
169. CIUREA A, Finckh A
     Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand et al.
     Ann Rheum Dis. 2023;82:e33.
     PubMed    
     
     
     January 2023
170. DOUGADOS M, Charles-Schoeman C, Szekanecz Z, Giles JT, et al
     Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
     Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406.
     PubMed    
     
     
     
171. NII T, Maeda Y, Motooka D, Naito M, et al
     Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis.
     Ann Rheum Dis. 2023 Jan 10:annrheumdis-2022-222881. doi: 10.1136/ard-2022-222881
     PubMed     Abstract available
     
     
     
172. KERSCHBAUMER A, Stimakovits NM, Smolen JS, Stefanova T, et al
     Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
     Ann Rheum Dis. 2023 Jan 10:ard-2022-223349. doi: 10.1136/ard-2022-223349.
     PubMed     Abstract available
     
     
     
173. POPE JE, Fleischmann RM
     Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
     Ann Rheum Dis. 2023 Jan 6:ard-2022-223071. doi: 10.1136/ard-2022-223071.
     PubMed    
     
     
     
174. GWINNUTT JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, et al
     2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.
     Ann Rheum Dis. 2023;82:48-56.
     PubMed     Abstract available
     
     
     
175. VAN MULLIGEN E, de Jong PHP
     Response to: 'Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis' by Garcia et al.
     Ann Rheum Dis. 2023;82:e10.
     PubMed    
     
     
     
176. GARCIA IE, Abud-Mendoza C
     Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis'.
     Ann Rheum Dis. 2023;82:e9.
     PubMed    
     
     
     
177. JONG GP, Pan LF, Lin TK, Chen HY, et al
     Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease'.
     Ann Rheum Dis. 2023;82:e11.
     PubMed    
     
     
     
178. LOGSTRUP BB, Olesen KKW, Masic D, Gyldenkerne C, et al
     Response to 'Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease" by Jong et al.
     Ann Rheum Dis. 2023;82:e12.
     PubMed    
     
     
     
179. SCHULZE-KOOPS H, Skapenko A, Krause A, Krueger K, et al
     Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
     Ann Rheum Dis. 2023;82:e1.
     PubMed    
     
     
     
180. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
     Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al.
     Ann Rheum Dis. 2023;82:e2.
     PubMed    
     
     
     December 2022
181. HEBING RC, Lin M, Bulatovic Calasan M, Muller IB, et al
     Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial.
     Ann Rheum Dis. 2022 Dec 21:ard-2022-223398. doi: 10.1136/ard-2022-223398.
     PubMed     Abstract available
     
     
     
182. VAN OUWERKERK L, Boers M, Emery P, de Jong PH, et al
     Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Dec 16:ard-2022-223443. doi: 10.1136/ard-2022-223443.
     PubMed     Abstract available
     
     
     
183. KRONZER VL, Sparks JA
     Occupational inhalants, genetics and the respiratory mucosal paradigm for ACPA-positive rheumatoid arthritis.
     Ann Rheum Dis. 2022 Dec 6:ard-2022-223286. doi: 10.1136/ard-2022-223286.
     PubMed    
     
     
     
184. TANG B, Liu Q, Ilar A, Wiebert P, et al
     Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking.
     Ann Rheum Dis. 2022 Dec 6:ard-2022-223134. doi: 10.1136/ard-2022-223134.
     PubMed     Abstract available
     
     
     
185. CURTIS JR, Yamaoka K, Chen YH, Bhatt DL, et al
     Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
     Ann Rheum Dis. 2022 Dec 5:annrheumdis-2022-222543. doi: 10.1136/ard-2022-222543.
     PubMed     Abstract available
     
     
     
186. CALISKAN Y
     News from EULAR.
     Ann Rheum Dis. 2022;81:1767.
     PubMed    
     
     
     
187. KAWANO Y, Patel NJ, Wang X, Cook CE, et al
     Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
     Ann Rheum Dis. 2022;81:1742-1749.
     PubMed     Abstract available
     
     
     
188. PRINGLE S, Verstappen GM, Bootsma H, Kroese FGM, et al
     Role of interaction between B cells and epithelial cells in pSS.
     Ann Rheum Dis. 2022;81:e260.
     PubMed    
     
     
     
189. RIVIERE E, Mariette X, Nocturne G
     Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle et al.
     Ann Rheum Dis. 2022;81:e261.
     PubMed    
     
     
     
190. WU BY, Chan CH, Wei JC
     Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'.
     Ann Rheum Dis. 2022;81:e243.
     PubMed    
     
     
     
191. HE P, Zhu H, Wu LF, Deng FY, et al
     Response to 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu.
     Ann Rheum Dis. 2022;81:e259.
     PubMed    
     
     
     
192. WANG H, Niu L
     Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'.
     Ann Rheum Dis. 2022;81:e258.
     PubMed    
     
     
     November 2022
193. SOLOMON DH, Giles JT, Liao KP, Ridker PM, et al
     Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Nov 30:ard-2022-223302. doi: 10.1136/ard-2022-223302.
     PubMed     Abstract available
     
     
     
194. BERGSTRA SA, Sepriano A, Kerschbaumer A, van der Heijde D, et al
     Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
     Ann Rheum Dis. 2022 Nov 21:ard-2022-223358. doi: 10.1136/ard-2022-223358.
     PubMed     Abstract available
     
     
     
195. SEPRIANO A, Kerschbaumer A, Bergstra SA, Smolen JS, et al
     Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
     Ann Rheum Dis. 2022 Nov 14. pii: ard-2022-223357. doi: 10.1136/ard-2022-223357.
     PubMed     Abstract available
     
     
     
196. KERSCHBAUMER A, Sepriano A, Bergstra SA, Smolen JS, et al
     Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
     Ann Rheum Dis. 2022 Nov 11. pii: ard-2022-223365. doi: 10.1136/ard-2022-223365.
     PubMed     Abstract available
     
     
     
197. SMOLEN JS, Landewe RBM, Bergstra SA, Kerschbaumer A, et al
     EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
     Ann Rheum Dis. 2022 Nov 10. pii: ard-2022-223356. doi: 10.1136/ard-2022-223356.
     PubMed     Abstract available
     
     
     
198. PAPPAS DA, St John G, Etzel CJ, Fiore S, et al
     Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US
     Ann Rheum Dis. 2022;81:e225.
     PubMed    
     
     
     
199. ZHENG W, Leong PY, Wei JC
     Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry stu
     Ann Rheum Dis. 2022;81:e224.
     PubMed    
     
     
     
200. KEDOR C, Zernicke J, Feist E
     Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
     Ann Rheum Dis. 2022;81:e234.
     PubMed    
     
     
     
201. RUSCITTI P, Stamm TA, Giacomelli R
     Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
     Ann Rheum Dis. 2022;81:e233.
     PubMed    
     
     
     
202. MURAVIOV Y, Muraviova L
     Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'.
     Ann Rheum Dis. 2022;81:e232.
     PubMed    
     
     
     
203. RUSCITTI P, Bruno F, Berardicurti O, Acanfora C, et al
     Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti et al' by Ch
     Ann Rheum Dis. 2022;81:e221.
     PubMed    
     
     
     October 2022
204. STUDENIC P, Aletaha D, de Wit M, Stamm TA, et al
     American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.
     Ann Rheum Dis. 2022 Oct 24. pii: ard-2022-223413. doi: 10.1136/ard-2022-223413.
     PubMed     Abstract available
     
     
     
205. ZHENG Z, Chang L, Mu J, Ni Q, et al
     Database of synovial T cell repertoire of rheumatoid arthritis patients identifies cross-reactive potential against pathogens including unencountered SARS-CoV-2.
     Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222763. doi: 10.1136/ard-2022-222763.
     PubMed    
     
     
     
206. GESSL I, Hana CA, Deimel T, Durechova M, et al
     Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis.
     Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222787. doi: 10.1136/ard-2022-222787.
     PubMed     Abstract available
     
     
     
207. TU J, Chen W, Fang Y, Han D, et al
     PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes.
     Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222708. doi: 10.1136/ard-2022-222708.
     PubMed     Abstract available
     
     
     
208. HOISNARD L, Pina Vegas L, Dray-Spira R, Weill A, et al
     Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
     Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222824. doi: 10.1136/ard-2022-222824.
     PubMed     Abstract available
     
     
     
209. DOUMEN M, Pazmino S, Bertrand D, De Cock D, et al
     Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response.
     Ann Rheum Dis. 2022;81:1385-1391.
     PubMed     Abstract available
     
     
     
210. YANG Y, He X, Yao M, Xing W, et al
     Response to: 'Correspondence to: 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'' by Ma et al.
     Ann Rheum Dis. 2022;81:e207.
     PubMed    
     
     
     
211. MA KS, Wang LT, Tsai SY
     Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.
     Ann Rheum Dis. 2022;81:e206.
     PubMed    
     
     
     
212. VAN MULLIGEN E, de Jong PHP
     Response to: 'Tapering antirheumatic drugs in a resource-poor setting: real-world evidence' by Haroon et al.
     Ann Rheum Dis. 2022;81:e209.
     PubMed    
     
     
     
213. HAROON M, Khan Z, Aamer M
     Tapering antirheumatic drugs in a resource-poor setting: real-world evidence.
     Ann Rheum Dis. 2022;81:e208.
     PubMed    
     
     
     
214. ANSARIN K, Taghizadieh A, Safiri S, Malek Mahdavi A, et al
     COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs.
     Ann Rheum Dis. 2022;81:e190.
     PubMed    
     
     
     September 2022
215. MOLANDER V, Bower H, Frisell T, Delcoigne B, et al
     Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Sep 23. pii: ard-2022-223050. doi: 10.1136/ard-2022-223050.
     PubMed     Abstract available
     
     
     
216. CHARLES-SCHOEMAN C, Buch MH, Dougados M, Bhatt DL, et al
     Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
     Ann Rheum Dis. 2022 Sep 22. pii: ard-2022-222259. doi: 10.1136/ard-2022-222259.
     PubMed     Abstract available
     
     
     
217. FEIST E, Fatenejad S, Grishin S, Korneva E, et al
     Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled
     Ann Rheum Dis. 2022 Sep 15. pii: ard-2022-222630. doi: 10.1136/ard-2022-222630.
     PubMed     Abstract available
     
     
     August 2022
218. CHENG M, Zhao Y, Cui Y, Zhong C, et al
     Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis.
     Ann Rheum Dis. 2022 Aug 19. pii: ard-2022-222871. doi: 10.1136/ard-2022-222871.
     PubMed     Abstract available
     
     
     
219. BALANESCU AR, Citera G, Pascual-Ramos V, Bhatt DL, et al
     Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
     Ann Rheum Dis. 2022 Aug 3. pii: ard-2022-222405. doi: 10.1136/ard-2022-222405.
     PubMed     Abstract available
     
     
     
220. HUGLE T
     Learning from chess engines: how reinforcement learning could redefine clinical decision-making in rheumatology.
     Ann Rheum Dis. 2022;81:1072-1075.
     PubMed    
     
     
     
221. CARDENAS-DE LA GARZA JA, Arvizu-Rivera RI, Galarza-Delgado DA
     Should patients starting biologics be screened for COVID-19?
     Ann Rheum Dis. 2022;81:e150.
     PubMed    
     
     
     July 2022
222. SMEELE HTW, Roder E, Mulders AGMGJ, Steegers EAP, et al
     Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring.
     Ann Rheum Dis. 2022 Jul 11. pii: ard-2022-222679. doi: 10.1136/ard-2022-222679.
     PubMed     Abstract available
     
     
     
223. SEROR R, Baron G, Camus M, Cornec D, et al
     Development and preliminary validation of the Sjogren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren's syndrome.
     Ann Rheum Dis. 2022;81:979-989.
     PubMed     Abstract available
     
     
     
224. BAI W, Liu H, Dou L, Yang Y, et al
     Pilot study of baricitinib for active Sjogren's syndrome.
     Ann Rheum Dis. 2022;81:1050-1052.
     PubMed    
     
     
     
225. VAN DER MEULEN TA, Vissink A, Bootsma H, Spijkervet FKL, et al
     Microbiome in Sjogren's syndrome: here we are.
     Ann Rheum Dis. 2022;81:e114.
     PubMed    
     
     
     
226. MANASSON J, Blank RB, Scher JU
     Response to: 'Microbiome in Sjogren's syndrome: here we are' by van der Meulen et al.
     Ann Rheum Dis. 2022;81:e115.
     PubMed    
     
     
     June 2022
227. QIN Y, Cai ML, Jin HZ, Huang W, et al
     Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-alpha-mediated ERK1/2 and JAK-STAT1 pathways.
     Ann Rheum Dis. 2022 Jun 27. pii: ard-2022-222605. doi: 10.1136/ard-2022-222605.
     PubMed     Abstract available
     
     
     
228. KERSCHBAUMER A, Rivai ZI, Smolen JS, Aletaha D, et al
     Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.
     Ann Rheum Dis. 2022 Jun 20. pii: annrheumdis-2021-221807.
     PubMed     Abstract available
     
     
     
229. NEMETH T, Nagy G, Pap T
     Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
     Ann Rheum Dis. 2022 Jun 17. pii: annrheumdis-2021-222021.
     PubMed     Abstract available
     
     
     
230. LAUPER K, Ludici M, Mongin D, Bergstra SA, et al
     Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
     Ann Rheum Dis. 2022 Jun 15. pii: annrheumdis-2022-222586.
     PubMed     Abstract available
     
     
     
231. VISMAN IM, Boers M, Vedder D, Twisk JW, et al
     Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years.
     Ann Rheum Dis. 2022 Jun 14. pii: annrheumdis-2022-222207.
     PubMed    
     
     
     
232. COOLES FAH, Tarn J, Lendrem DW, Naamane N, et al
     Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
     Ann Rheum Dis. 2022 Jun 9. pii: annrheumdis-2022-222370.
     PubMed     Abstract available
     
     
     
233. KVIEN TK
     EULAR 75-year anniversary: commentaries on key ARD papers from 1947.
     Ann Rheum Dis. 2022;81:751-752.
     PubMed    
     
     
     
234. DELCOIGNE B, Ljung L, Provan SA, Glintborg B, et al
     Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
     Ann Rheum Dis. 2022;81:789-797.
     PubMed     Abstract available
     
     
     
235. DROSOS GC, Vedder D, Houben E, Boekel L, et al
     EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
     Ann Rheum Dis. 2022;81:768-779.
     PubMed     Abstract available
     
     
     
236. RUSCITTI P, Stamm TA, Giacomelli R
     Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease.
     Ann Rheum Dis. 2022;81:e103.
     PubMed    
     
     
     
237. KEDOR C, Listing J, Zernicke J, Feist E, et al
     Response to: 'Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease' by Ruscitti et al.
     Ann Rheum Dis. 2022;81:e104.
     PubMed    
     
     
     
238. MINOIA F, Ravelli A
     Response to: 'Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome' by Zhang et al.
     Ann Rheum Dis. 2022;81:e100.
     PubMed    
     
     
     
239. ZHANG L, Yang X, Li TF, Liu X, et al
     Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease-associated macrophage activation syndrome.
     Ann Rheum Dis. 2022;81:e99.
     PubMed    
     
     
     May 2022
240. BOERS M, Hartman L, Opris-Belinski D, Bos R, et al
     Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
     Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2021-221957.
     PubMed     Abstract available
     
     
     
241. DAIEN C, Krogulec M, Gineste P, Steens JM, et al
     Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFalpha therapy: a placebo-controlled phase II study.
     Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2022-222228.
     PubMed     Abstract available
     
     
     
242. BUGATTI S, De Stefano L, D'Onofrio B, Nicrosini A, et al
     Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 May 27. pii: annrheumdis-2022-222436.
     PubMed     Abstract available
     
     
     
243. ROUDIER J
     Correspondence on "Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis" by Maggi et al.
     Ann Rheum Dis. 2022 May 20. pii: annrheumdis-2022-222750.
     PubMed    
     
     
     
244. ROSENBAUM JT, Gill T, Martin TM, Friedman M, et al
     Marking the 50th anniversary of a seminal paper in rheumatology: did Baruj Benacerraf and Hugh McDevitt get it right?
     Ann Rheum Dis. 2022;81:618-621.
     PubMed    
     
     
     
245. BROEREN MGA, Wang JJ, Balzaretti G, Groenen PJTA, et al
     Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjogren's syndrome.
     Ann Rheum Dis. 2022;81:644-652.
     PubMed     Abstract available
     
     
     
246. BUCH MH, Maksymowych WP, Boers M
     Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies.
     Ann Rheum Dis. 2022;81:741-742.
     PubMed    
     
     
     April 2022
247. DE STEFANO L, D'Onofrio B, Sakellariou G, Manzo A, et al
     Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic.
     Ann Rheum Dis. 2022 Apr 29. pii: annrheumdis-2022-222264.
     PubMed    
     
     
     
248. VAN OUWERKERK L, Palmowski A, Nevins IS, Buttgereit F, et al
     Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2022-222338.
     PubMed     Abstract available
     
     
     
249. SAEVARSDOTTIR S, Stefansdottir L, Sulem P, Thorleifsson G, et al
     Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
     Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2021-221754.
     PubMed     Abstract available
     
     
     
250. REIJM S, Brehler AS, Rantapaa-Dahlqvist S, Kawakami A, et al
     Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis.
     Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2022-222326.
     PubMed    
     
     
     
251. MAGGI J, Carrascal M, Soto L, Neira O, et al
     Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis.
     Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2021-220371.
     PubMed     Abstract available
     
     
     
252. VAN LINT JA, van Hunsel FPAM, Tas SW, Vonkeman HE, et al
     Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
     Ann Rheum Dis. 2022;81:597-599.
     PubMed    
     
     
     
253. SAPER VE, Chen G, Guillerman RP, Khatri P, et al
     Response to: 'Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al.
     Ann Rheum Dis. 2022;81:e62.
     PubMed    
     
     
     
254. STUDENIC P, Felson DT, de Wit M, Smolen JS, et al
     Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti et al.
     Ann Rheum Dis. 2022;81:e56.
     PubMed    
     
     
     March 2022
255. VERSTAPPEN M, Huizinga TW, van der Helm-van Mil AH
     No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years.
     Ann Rheum Dis. 2022 Mar 2. pii: annrheumdis-2022-222145.
     PubMed    
     
     
     
256. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
     Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
     Ann Rheum Dis. 2022;81:433-439.
     PubMed     Abstract available
     
     
     
257. LIU D, Zhang F, Cao H, Wang X, et al
     Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?
     Ann Rheum Dis. 2022;81:e36.
     PubMed    
     
     
     
258. YAMAMOTO M, Yoshikawa N, Tanaka H
     Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis.
     Ann Rheum Dis. 2022;81:e50.
     PubMed    
     
     
     
259. REGUEIRO C, Gonzalez A
     Questions on 'Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al.
     Ann Rheum Dis. 2022;81:e38.
     PubMed    
     
     
     
260. MARTINSSON K, Durholz K, Schett G, Zaiss MM, et al
     Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA.
     Ann Rheum Dis. 2022;81:445-447.
     PubMed    
     
     
     
261. SAPER VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, et al
     Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
     Ann Rheum Dis. 2022;81:406-415.
     PubMed     Abstract available
     
     
     
262. GHALANDARI N, Kemper E, Crijns IH, Wolbink G, et al
     Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy.
     Ann Rheum Dis. 2022;81:402-405.
     PubMed     Abstract available
     
     
     February 2022
263. ARAUJO CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, et al
     Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
     Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221916.
     PubMed     Abstract available
     
     
     
264. LOPEZ-ROMERO P, de la Torre I, Haladyj E, Aletaha D, et al
     Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221323.
     PubMed     Abstract available
     
     
     
265. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
     Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson et al.
     Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221941.
     PubMed    
     
     
     
266. FERREIRA RJO, Welsing PMJ, Jacobs JW, Gossec L, et al
     Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson et al.
     Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221917.
     PubMed    
     
     
     
267. JIN S, Jiang N, Huo Y, Duan X, et al
     Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations.
     Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2021-221841.
     PubMed    
     
     
     
268. TEDESCHI SK, Stratton J, Ellrodt JE, Whelan MG, et al
     Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.
     Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2022-222232.
     PubMed    
     
     
     
269. MEDEIROS-RIBEIRO AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, et al
     Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
     Ann Rheum Dis. 2022 Feb 8. pii: annrheumdis-2021-221735.
     PubMed     Abstract available
     
     
     
270. SYMONS RA, Colella F, Collins FL, Rafipay AJ, et al
     Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis.
     Ann Rheum Dis. 2022;81:214-224.
     PubMed     Abstract available
     
     
     
271. VAN DER HELM-VAN MIL A, Landewe RB
     Response to: 'The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis' by Rothschild.
     Ann Rheum Dis. 2022;81:e19.
     PubMed    
     
     
     
272. ROTHSCHILD BM
     The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis.
     Ann Rheum Dis. 2022;81:e18.
     PubMed    
     
     
     January 2022
273. KHOSROW-KHAVAR F, Kim SC, Lee H, Lee SB, et al
     Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
     Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-221915.
     PubMed     Abstract available
     
     
     
274. GE C, Weisse S, Xu B, Dobritzsch D, et al
     Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor.
     Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-220500.
     PubMed     Abstract available
     
     
     
275. 
     Correction: Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis.
     Ann Rheum Dis. 2022;81:e17.
     PubMed    
     
     
     
276. LEE YH
     Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study.
     Ann Rheum Dis. 2022;81:e3.
     PubMed    
     
     
     
277. INAMO J
     Response to: 'Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Lee.
     Ann Rheum Dis. 2022;81:e4.
     PubMed    
     
     
     
278. KISSEL T, van Wesemael TJ, Lundquist A, Kokkonen H, et al
     Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA.
     Ann Rheum Dis. 2022;81:141-143.
     PubMed    
     
     
     December 2021
279. BUGATTI S, De Stefano L, Balduzzi S, Greco MI, et al
     Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
     Ann Rheum Dis. 2021;80:1635-1638.
     PubMed    
     
     
     
280. ROSENZWAJG M, Lorenzon R, Klatzmann D
     Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al.
     Ann Rheum Dis. 2021;80:e197.
     PubMed    
     
     
     
281. MEYER A, Wittekind PS, Kotschenreuther K, Schiller J, et al
     Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
     Ann Rheum Dis. 2021;80:e196.
     PubMed    
     
     
     
282. PEREZ-GARCIA LF, Roder E, Goekoop RJ, Hazes JMW, et al
     Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility).
     Ann Rheum Dis. 2021;80:1545-1552.
     PubMed     Abstract available
     
     
     
283. GRAALMANN T, Borst K, Manchanda H, Vaas L, et al
     B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner.
     Ann Rheum Dis. 2021;80:1537-1544.
     PubMed     Abstract available
     
     
     November 2021
284. SIMADER E, Tobudic S, Mandl P, Haslacher H, et al
     Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
     Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221347.
     PubMed     Abstract available
     
     
     
285. BALSA A, Garcia de Yebenes MJ, Carmona L
     Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.
     Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221163.
     PubMed     Abstract available
     
     
     
286. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
     Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment.
     Ann Rheum Dis. 2021 Nov 16. pii: annrheumdis-2021-221653.
     PubMed    
     
     
     
287. SIDDLE HJ, Chapman LS, Mankia K, Zabalan C, et al
     Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.
     Ann Rheum Dis. 2021 Nov 8. pii: annrheumdis-2021-221160.
     PubMed     Abstract available
     
     
     
288. WINTHROP KL, Tanaka Y, Takeuchi T, Kivitz A, et al
     Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
     Ann Rheum Dis. 2021 Nov 5. pii: annrheumdis-2021-221051.
     PubMed     Abstract available
     
     
     
289. TANAKA Y, Oba K, Takeuchi T
     Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
     Ann Rheum Dis. 2021;80:e173.
     PubMed    
     
     
     
290. BERKHOUT LC, l'Ami MJ, Wolbink GJ, Rispens T, et al
     Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.
     Ann Rheum Dis. 2021;80:e172.
     PubMed    
     
     
     
291. CHEN MH, Lee IC, Chen MH, Hou MC, et al
     Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.
     Ann Rheum Dis. 2021;80:1393-1399.
     PubMed     Abstract available
     
     
     
292. NABI H, Georgiadis S, Loft AG, Hendricks O, et al
     Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
     Ann Rheum Dis. 2021;80:1400-1409.
     PubMed     Abstract available
     
     
     October 2021
293. TAYLOR PC, Takeuchi T, Burmester GR, Durez P, et al
     Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
     Ann Rheum Dis. 2021 Oct 27. pii: annrheumdis-2021-221276.
     PubMed     Abstract available
     
     
     
294. LI X, Tong X, Yeung WWY, Kuan P, et al
     Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
     Ann Rheum Dis. 2021 Oct 22. pii: annrheumdis-2021-221571.
     PubMed     Abstract available
     
     
     
295. CHRISTENSEN IE, Lillegraven S, Mielnik P, Bakland G, et al
     Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
     Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-221007.
     PubMed     Abstract available
     
     
     
296. IBANEZ-COSTA A, Perez-Sanchez C, Patino-Trives AM, Luque-Tevar M, et al
     Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.
     Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-220308.
     PubMed     Abstract available
     
     
     
297. WINTHROP KL, Nash P, Yamaoka K, Mysler E, et al
     Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
     Ann Rheum Dis. 2021 Oct 6. pii: annrheumdis-2021-220822.
     PubMed     Abstract available
     
     
     
298. CAPELUSNIK D, Aletaha D
     Baseline predictors of different types of treatment success in rheumatoid arthritis.
     Ann Rheum Dis. 2021 Oct 4. pii: annrheumdis-2021-220853.
     PubMed     Abstract available
     
     
     
299. FLOUDAS A, Neto N, Orr C, Canavan M, et al
     Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
     Ann Rheum Dis. 2021 Oct 1. pii: annrheumdis-2021-220458.
     PubMed     Abstract available
     
     
     
300. MEEHAN GR, Thomas R, Al Khabouri S, Wehr P, et al
     Preclinical models of arthritis for studying immunotherapy and immune tolerance.
     Ann Rheum Dis. 2021;80:1268-1277.
     PubMed     Abstract available
     
     
     
301. NIKIPHOROU E, Santos EJF, Marques A, Bohm P, et al
     2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.
     Ann Rheum Dis. 2021;80:1278-1285.
     PubMed     Abstract available
     
     
     September 2021
302. YOSHII I, Sawada N, Chijiwa T, Kokei S, et al
     Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis.
     Ann Rheum Dis. 2021 Sep 11. pii: annrheumdis-2021-221093.
     PubMed    
     
     
     
303. MINOIA F, Ravelli A
     Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang et al.
     Ann Rheum Dis. 2021;80:e146.
     PubMed    
     
     
     
304. WANG R, Li T, Ye S, Tan W, et al
     Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.
     Ann Rheum Dis. 2021;80:e145.
     PubMed    
     
     
     
305. OZEN G, Michaud K
     Response to: 'Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et al.
     Ann Rheum Dis. 2021;80:e141.
     PubMed    
     
     
     
306. JONSSON R
     Henrik Sjogren (1899-1986): the syndrome and his legacy.
     Ann Rheum Dis. 2021;80:1108-1109.
     PubMed    
     
     
     
307. MAASSEN JM, Dos Santos Sobrin R, Bergstra SA, Goekoop R, et al
     Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.
     Ann Rheum Dis. 2021;80:1124-1129.
     PubMed     Abstract available
     
     
     
308. LIOU YS, Lin TK, Chen HY, Jong GP, et al
     Medications associated with fracture risk in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2021;80:e140.
     PubMed    
     
     
     August 2021
309. HECKERT SL, Bergstra SA, Matthijssen XME, Goekoop-Ruiterman YPM, et al
     Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course.
     Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220882.
     PubMed     Abstract available
     
     
     
310. WANG Y, Xie X, Zhang C, Su M, et al
     Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome shared megakaryocyte expansion in peripheral blood.
     Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220066.
     PubMed     Abstract available
     
     
     
311. WALLACE ZS, Sparks JA, Robinson PC, Machado PM, et al
     Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220960.
     PubMed    
     
     
     
312. GREMESE E, Ferraccioli G
     Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220932.
     PubMed    
     
     
     
313. NAGY G, Roodenrijs NMT, Welsing PMJ, Kedves M, et al
     EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
     Ann Rheum Dis. 2021 Aug 18. pii: annrheumdis-2021-220973.
     PubMed     Abstract available
     
     
     
314. VAN VOLLENHOVEN RF, Tas SW, Nurmohamed MT
     Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221146.
     PubMed    
     
     
     
315. HOLTEN K, Paulshus Sundlisater N, Lillegraven S, Sexton J, et al
     Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.
     Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-220750.
     PubMed     Abstract available
     
     
     
316. SPARKS JA, Wallace ZS, Seet AM, Robinson PC, et al
     Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221157.
     PubMed    
     
     
     
317. PLATZER A, Alasti F, Smolen JS, Aletaha D, et al
     Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables.
     Ann Rheum Dis. 2021 Aug 10. pii: annrheumdis-2021-220331.
     PubMed     Abstract available
     
     
     
318. MANKIA K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, et al
     EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
     Ann Rheum Dis. 2021 Aug 6. pii: annrheumdis-2021-220884.
     PubMed     Abstract available
     
     
     
319. NASONOV E, Fatenejad S, Feist E, Ivanova M, et al
     Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
     Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-219876.
     PubMed     Abstract available
     
     
     
320. SPARKS JA
     Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease.
     Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220856.
     PubMed    
     
     
     
321. PALOMAKI A, Palotie A, Koskela J, Eklund KK, et al
     Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.
     Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220698.
     PubMed     Abstract available
     
     
     
322. VALLEJO-YAGUE E, Keystone EC, Kandhasamy S, Micheroli R, et al
     Primary and secondary non-response: in need of operational definitions in observational studies.
     Ann Rheum Dis. 2021;80:961-964.
     PubMed    
     
     
     
323. NAKAMURA H, Tanaka T, Pranzatelli T, Ji Y, et al
     Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjogren's syndrome-like phenotype in mice.
     Ann Rheum Dis. 2021;80:1031-1039.
     PubMed     Abstract available
     
     
     
324. WANG H, Stewart S, Darlow B, Horgan B, et al
     Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016-2020.
     Ann Rheum Dis. 2021;80:1095-1096.
     PubMed    
     
     
     
325. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
     Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
     Ann Rheum Dis. 2021;80:1086-1093.
     PubMed     Abstract available
     
     
     
326. MATTHIJSSEN XME, Wouters F, Sidhu N, Niemantsverdriet E, et al
     Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study.
     Ann Rheum Dis. 2021;80:974-980.
     PubMed     Abstract available
     
     
     
327. ASSAN F, Seror R, Mariette X, Nocturne G, et al
     New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS.
     Ann Rheum Dis. 2021;80:e122.
     PubMed    
     
     
     July 2021
328. REDEKER I, Albrecht K, Kekow J, Burmester GR, et al
     Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
     Ann Rheum Dis. 2021 Jul 28. pii: annrheumdis-2021-220651.
     PubMed     Abstract available
     
     
     
329. WOUTERS F, Maurits MP, van Boheemen L, Verstappen M, et al
     Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jul 20. pii: annrheumdis-2021-220546.
     PubMed     Abstract available
     
     
     
330. 
     Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jul 6. pii: annrheumdis-2017-211351.
     PubMed    
     
     
     
331. DUMOULIN QA, Matthijssen XME, Wouters F, Krijbolder DI, et al
     Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'.
     Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220511.
     PubMed    
     
     
     
332. GESSL I, Aletaha D, Mandl P
     Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin et al.
     Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220922.
     PubMed    
     
     
     
333. OCON AJ, Reed G, Pappas DA, Curtis JR, et al
     Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jul 2. pii: annrheumdis-2021-220577.
     PubMed     Abstract available
     
     
     
334. WONG AY, MacKenna B, Morton CE, Schultze A, et al
     Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
     Ann Rheum Dis. 2021;80:943-951.
     PubMed     Abstract available
     
     
     
335. JOUSSE-JOULIN S, D'Agostino MA, Hocevar A, Naredo E, et al
     Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's sy
     Ann Rheum Dis. 2021;80:e112.
     PubMed    
     
     
     
336. LAI SW, Kuo YH, Liao KF
     Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease.
     Ann Rheum Dis. 2021;80:e105.
     PubMed    
     
     
     
337. COIFFIER G, Martel A, Albert JD, Lescoat A, et al
     Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?
     Ann Rheum Dis. 2021;80:e111.
     PubMed    
     
     
     
338. TRAVES PG, Murray B, Campigotto F, Galien R, et al
     JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
     Ann Rheum Dis. 2021;80:865-875.
     PubMed     Abstract available
     
     
     June 2021
339. JAIN S, Dhir V
     Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'.
     Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220816.
     PubMed    
     
     
     
340. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
     Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir et al.
     Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220857.
     PubMed    
     
     
     
341. ALBACH FN, Burmester GR, Biesen R
     Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
     Ann Rheum Dis. 2021 Jun 24. pii: annrheumdis-2021-220834.
     PubMed    
     
     
     
342. SHIPA MRA, Amarnani R, Yeoh SA, Mainuddin MD, et al
     Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy.
     Ann Rheum Dis. 2021 Jun 23. pii: annrheumdis-2021-220642.
     PubMed    
     
     
     
343. JAIN S, Dhir V, Aggarwal A, Gupta R, et al
     Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial.
     Ann Rheum Dis. 2021 Jun 10. pii: annrheumdis-2021-220512.
     PubMed     Abstract available
     
     
     
344. PAULSHUS SUNDLISATER N, Aga AB, Olsen IC, Hammer HB, et al
     Joint tenderness and ultrasound inflammation in DMARD-naive patients with early rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jun 3. pii: annrheumdis-2021-220265.
     PubMed    
     
     
     
345. CROW MK
     Charles L Christian: model physician scientist and mentor.
     Ann Rheum Dis. 2021;80:685-688.
     PubMed    
     
     
     
346. ANSALONE C, Cole J, Chilaka S, Sunzini F, et al
     TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors.
     Ann Rheum Dis. 2021;80:748-757.
     PubMed     Abstract available
     
     
     
347. HAYER S, Vervoordeldonk MJ, Denis MC, Armaka M, et al
     'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models.
     Ann Rheum Dis. 2021;80:714-726.
     PubMed     Abstract available
     
     
     May 2021
348. SPARKS JA, Wallace ZS, Seet AM, Gianfrancesco MA, et al
     Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
     Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220418.
     PubMed     Abstract available
     
     
     
349. JOHNSON TM, Sayles HR, Baker JF, George MD, et al
     Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
     Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220125.
     PubMed     Abstract available
     
     
     
350. D'ONOFRIO B, De Stefano L, Palermo BL, Xoxi B, et al
     Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220219.
     PubMed    
     
     
     
351. LIN TK, Pan LF, Jong GP
     Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220453.
     PubMed    
     
     
     
352. GONG Z, Zhang F
     Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220494.
     PubMed    
     
     
     
353. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
     Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin et al.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220477.
     PubMed    
     
     
     
354. TAKANASHI S, Kaneko Y, Takeuchi T
     Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.
     Ann Rheum Dis. 2021 May 7. pii: annrheumdis-2021-220315.
     PubMed    
     
     
     
355. 
     Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
     Ann Rheum Dis. 2021;80:e83.
     PubMed    
     
     
     
356. ROGIER C, van Dijk BT, Brouwer E, de Jong PHP, et al
     Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints.
     Ann Rheum Dis. 2021;80:668-669.
     PubMed    
     
     
     
357. SCHULZE-KOOPS H, Krueger K, Vallbracht I, Hasseli R, et al
     Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
     Ann Rheum Dis. 2021;80:e67.
     PubMed    
     
     
     
358. ROMAO VC, Cruz-Machado AR, Fonseca JE
     Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al.
     Ann Rheum Dis. 2021;80:e76.
     PubMed    
     
     
     
359. ZHAO J, Pang R, Wu J, Guo Y, et al
     Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences.
     Ann Rheum Dis. 2021;80:e63.
     PubMed    
     
     
     
360. MOENTADJ R, Wang Y, Bowerman K, Rehaume L, et al
     Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice.
     Ann Rheum Dis. 2021;80:573-581.
     PubMed     Abstract available
     
     
     
361. KAJIO N, Takeshita M, Suzuki K, Kaneda Y, et al
     Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.
     Ann Rheum Dis. 2021;80:651-659.
     PubMed     Abstract available
     
     
     April 2021
362. ROONGTA R, Chattopadhyay A, Ghosh A
     Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'
     Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220479.
     PubMed    
     
     
     
363. DERKSEN VFAM, van der Woude D
     Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'' by Roongta et al.
     Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220516.
     PubMed    
     
     
     
364. INGEGNOLI F, Cincinelli G, Luppino AF, Favalli EG, et al
     Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
     Ann Rheum Dis. 2021 Apr 13. pii: annrheumdis-2021-220142.
     PubMed    
     
     
     
365. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
     Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
     Ann Rheum Dis. 2021 Apr 7. pii: annrheumdis-2020-219699.
     PubMed     Abstract available
     
     
     
366. XIE W, Huang H, Li G, Hao Y, et al
     Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
     Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-220112.
     PubMed     Abstract available
     
     
     
367. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
     Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
     Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2020-219825.
     PubMed     Abstract available
     
     
     
368. SO H, Cheng IT, Lau SL, Chow E, et al
     Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
     Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-219846.
     PubMed     Abstract available
     
     
     
369. GUPTA L, Misra DP, Agarwal V, Balan S, et al
     Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al.
     Ann Rheum Dis. 2021;80:e47.
     PubMed    
     
     
     March 2021
370. FELTEN R, Devauchelle-Pensec V, Seror R, Duffau P, et al
     Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial.
     Ann Rheum Dis. 2021;80:329-338.
     PubMed     Abstract available
     
     
     
371. BAER AN, Gottenberg JE, St Clair EW, Sumida T, et al
     Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial.
     Ann Rheum Dis. 2021;80:339-348.
     PubMed     Abstract available
     
     
     
372. AKIYAMA S, Hamdeh S, Micic D, Sakuraba A, et al
     Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
     Ann Rheum Dis. 2021;80:384-391.
     PubMed     Abstract available
     
     
     
373. LIEW JW, Graef ER
     Rheumatic disease and COVID-19.
     Ann Rheum Dis. 2021;80:e43.
     PubMed    
     
     
     
374. MONTI S, Montecucco C
     Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
     Ann Rheum Dis. 2021;80:e40.
     PubMed    
     
     
     
375. WALLACE B, Washer L, Marder W, Kahlenberg JM, et al
     Patients with lupus with COVID-19: University of Michigan experience.
     Ann Rheum Dis. 2021;80:e35.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Rheumatoid Arthritis is free of charge.